Find comprehensive information on Papillary Thyroid Carcinoma, including clinical documentation, ICD-10 codes (C73), SNOMED CT concepts, medical coding guidelines, and healthcare resources. Learn about diagnosis, treatment options, pathology reports, and prognosis for Papillary Thyroid Cancer. This resource is for healthcare professionals, medical coders, and patients seeking information on Papillary Thyroid Neoplasm.
Also known as
Malignant neoplasm of thyroid gland
Cancers specifically affecting the thyroid gland.
Malignant neoplasm of thyroid, unspecified
Thyroid cancer where the specific type is not documented.
Personal history of malignant neoplasm of thyroid
Indicates a past diagnosis of thyroid cancer, now resolved.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the papillary thyroid cancer confirmed?
Incorrect coding of lateral neck lymph node involvement (level VI) with papillary thyroid cancer, impacting staging and reimbursement.
Inaccurate documentation of tumor size, crucial for T staging and subsequent treatment planning for thyroid cancer.
Confusing multifocal disease within the thyroid with extrathyroidal extension, leading to incorrect coding and staging.
Q: What are the most current ATA guidelines for the management of low-risk papillary thyroid microcarcinoma in asymptomatic patients?
A: The current American Thyroid Association (ATA) guidelines for managing low-risk papillary thyroid microcarcinoma (PTMC) less than 1 cm in asymptomatic patients often favor active surveillance rather than immediate surgery. These guidelines emphasize individualized patient-centered care, considering factors like patient age, comorbidities, and tumor characteristics. Specifically, the guidelines recommend active surveillance with periodic ultrasound monitoring for PTMC without evidence of extrathyroidal extension, lymph node metastasis, or distant metastases. Explore how risk stratification factors, including molecular testing, can inform decision-making regarding active surveillance versus surgical intervention. Consider implementing ATA guidelines into your clinical practice to provide the most up-to-date patient care. Learn more about the specific criteria defining low-risk PTMC and the recommended surveillance protocols within the ATA guidelines.
Q: How do I differentiate between benign thyroid nodules and papillary thyroid cancer using ultrasound features and fine-needle aspiration biopsy (FNAB) results, particularly when Bethesda categories III and IV are encountered?
A: Differentiating benign thyroid nodules from papillary thyroid cancer (PTC) often requires integrating ultrasound (US) features and fine-needle aspiration biopsy (FNAB) cytology. While some US features like hypoechogenicity, microcalcifications, and irregular margins raise suspicion for malignancy, they are not definitive. FNAB remains crucial, though Bethesda categories III (atypia of undetermined significance/follicular lesion of undetermined significance or AUS/FLUS) and IV (follicular neoplasm/suspicious for a follicular neoplasm or FN/SFN) present diagnostic challenges. For Bethesda III and IV, molecular testing can be considered to further risk-stratify the nodule. In addition, repeat FNAB or surgical excision may be necessary for definitive diagnosis. Correlating US features with cytology is essential, and consider implementing a multidisciplinary approach involving endocrinologists, cytopathologists, and surgeons, especially for indeterminate FNAB results. Learn more about the latest advances in molecular diagnostics for thyroid nodules and their role in clinical decision-making.
Patient presents with complaints concerning for thyroid cancer, including palpable thyroid nodule, dysphagia, or voice changes. Physical examination reveals a solitary thyroid nodule, possibly firm or fixed. Ultrasound of the thyroid demonstrates a hypoechoic nodule with irregular margins, microcalcifications, and increased vascularity, raising suspicion for papillary thyroid carcinoma. Fine needle aspiration biopsy (FNAB) of the thyroid nodule reveals cytology consistent with papillary thyroid cancer. Differential diagnosis includes follicular thyroid cancer, Hürthle cell carcinoma, medullary thyroid carcinoma, and benign thyroid nodules. Staging workup, including neck ultrasound and chest imaging, is performed to assess for lymph node involvement and distant metastasis. Based on the patient's presentation, imaging findings, and FNAB results, the diagnosis of papillary thyroid carcinoma is confirmed. Treatment options, including thyroidectomy (total or partial), radioactive iodine therapy, and thyroid hormone suppression therapy, are discussed with the patient. Risks and benefits of each treatment modality are explained, and a personalized treatment plan is developed. Patient education regarding thyroid cancer prognosis, follow-up care, and potential complications is provided. Referral to an endocrinologist and oncologist is made for ongoing management. ICD-10 code C73.9 for malignant neoplasm of thyroid gland, unspecified is assigned. CPT codes for the procedures performed, such as fine needle aspiration biopsy and thyroid ultrasound, are documented.